Bruker (NASDAQ:BRKR) Issues FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.100-2.150 for the period, compared to the consensus EPS estimate of 2.120. The company issued revenue guidance of $3.6 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Analyst Ratings Changes

A number of brokerages recently issued reports on BRKR. Citigroup decreased their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Guggenheim decreased their target price on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. TD Cowen upgraded Bruker to a “hold” rating in a report on Monday, April 13th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, April 24th. Finally, Jefferies Financial Group set a $50.00 price target on Bruker in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Bruker currently has an average rating of “Hold” and an average target price of $49.38.

Bruker Stock Up 11.3%

Shares of BRKR stock traded up $4.29 on Wednesday, reaching $42.30. 3,145,917 shares of the company’s stock traded hands, compared to its average volume of 1,924,247. Bruker has a 12-month low of $28.53 and a 12-month high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The company has a market capitalization of $6.44 billion, a P/E ratio of -282.00, a price-to-earnings-growth ratio of 2.28 and a beta of 1.12. The business’s 50 day moving average price is $37.18 and its two-hundred day moving average price is $42.01.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The firm had revenue of $823.40 million for the quarter, compared to the consensus estimate of $796.11 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a $0.05 dividend. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is -133.33%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 27.20% of the stock is owned by company insiders.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 results beat expectations — Bruker reported EPS of $0.31 vs. consensus $0.23 and revenue of $823.4M vs. $796.1M estimates, showing a quarter that topped analyst forecasts. Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management provided FY2026 EPS guidance (2.10–2.15) roughly in line with consensus, reducing uncertainty about the year and giving investors a clear earnings range to model. Bruker Earnings / Press Release & Transcript
• Neutral Sentiment: Revenue growth was modest (up ~2.7% YoY), indicating steady top‑line expansion but not a strong acceleration — the beat was driven mainly by execution rather than a big demand surge. Bruker: Q1 Earnings Snapshot
• Negative Sentiment: EPS declined versus the prior year (from $0.47 to $0.31) and net margin remains slightly negative (-0.25%), highlighting margin pressure and profit recovery still in progress. Bruker Earnings / Press Release & Transcript
• Negative Sentiment: Market concerns about earnings jitters and insider selling have been raised in recent commentary, which could cap upside if investors turn cautious despite the beat. Does Earnings Jitters And Insider Selling Change The Bull Case For Bruker (BRKR)?

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. Los Angeles Capital Management LLC purchased a new position in Bruker in the fourth quarter valued at about $26,000. Allworth Financial LP grew its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the last quarter. Summit Securities Group LLC acquired a new stake in shares of Bruker in the fourth quarter worth about $50,000. Finally, Parkside Financial Bank & Trust lifted its position in shares of Bruker by 144.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after buying an additional 876 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.